



an Open Access Journal by MDPI

Biological Treatment for Rheumatic Diseases

Guest Editor:

Dr. Kornelia Kuźnik-Trocha

Department of Clinical Chemistry
and Laboratory Diagnostics,
Faculty of Pharmaceutical
Sciences in Sosnowiec, Medical
University of Silesia, Katowice,
Poland

Deadline for manuscript
submissions:

30 December 2024

Message from the Guest Editor

The implementation of biological drugs into the treatment of rheumatic diseases has opened new possibilities in the management of diseases. The development of "targeted" therapies that are more effective at inhibiting bone and joint destruction has significantly improved the life quality of patients. However, not all patients respond positively to biological therapy. Moreover, the long-term use of biological drugs may be associated with a decrease in their efficacy as well as the occurrence of side effects related to the potential immunogenicity of these medicines. This is because biological drugs can induce an immune response and the synthesis of anti-drug antibodies. Therefore, it is important to understand the detailed mechanisms through which metabolic changes occur when using biological drugs. In this Special Issue, our goal is to bring together the results of expert research in this field, allowing us to better understand the effects of biological drugs on metabolic processes occurring in the body and provide an opportunity for medicines to be used more effectively in treating rheumatic diseases.



mdpi.com/si/198520

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com